Tumor-derived Mesenchymal Stem Cells Enhance Tumor Development Via Nitric Oxide (100.33)

Guangwen Ren,Liying Zhang,Ting Wen,Xin Zhao,Zeng-rong Yuan,Jimin Zhang,Weifang Ling,Andrew L'huiIIie,Changshun Shao,Yufang Shi

DOI: https://doi.org/10.4049/jimmunol.184.supp.100.33

2010-01-01

Abstract:Abstract Mesenchymal stem cells (MSCs) have been widely applied in treating immune disorders due to their immunosuppressive capacity. However, a major concern for the clinical application of MSCs is their risk to promote tumorigenesis. In the meantime, there are increasing reports about the identification of MSCs from various tumor tissues. In this study, we compared the tumor-derived MSCs with bone marrow-derived MSCs (BM-MSCs) in vitro and in vivo. We found that only tumor-derived MSCs, but not BM-MSCs enhance tumor development. In vitro, tumor-derived MSCs had a similar capacity to suppress T cell receptor-induced T cell proliferation via nitric oxide (NO), but exhibited a more vigorous inhibition on the differentiation and maturation of dendritic cells, compared to BM-MSCs. Moreover, co-culture with tumor-derived MSCs led bone marrow cells to differentiate into more CD11b+Gr-1+ myeloid-derived suppressor cells (MDSCs), another NO-producing immunosuppressive cell population. In vivo, more MDSCs were also detected after administration of tumor-derived MSCs, but not BM-MSCs in tumor-bearing mice. Furthermore, tumor-derived MSCs, but not BM-MSCs significantly enhanced tumor growth, which was partially dependent on NO. Therefore, NO-dependent tumor promoting effect is likely not mediated by MSCs themselves, but through the indirect action of MDSCs. Our findings indicate a novel role of MSCs in tumor progression and provide new information for the clinical application of MSCs.